This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bergshoeff, A. S.
Right arrow Articles by Burger, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bergshoeff, A. S.
Right arrow Articles by Burger, D. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2004, p. 1904-1907, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1904-1907.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of Indinavir Combined with Low-Dose Ritonavir in Human Immunodeficiency Virus Type 1-Infected Children

A. S. Bergshoeff,1,2* P. L. A. Fraaij,3 A. M. C. van Rossum,3 G. Verweel,3 L. H. Wynne,4 G. A. Winchell,4 R. Y. Leavitt,4 B.-Y. T. Nguyen,4 R. de Groot,3 and D. M. Burger1,2

University Medical Center, Department of Clinical Pharmacy,1 Nijmegen University Center for Infectious Diseases, Nijmegen,2 Erasmus MC/Sophia, Division of Pediatric Infectious Diseases and Immunology, Rotterdam, The Netherlands,3 Merck & Co., Inc., West Point, Pennsylvania4

Received 5 August 2003/ Returned for modification 9 October 2003/ Accepted 8 January 2004

So far, no pediatric doses for indinavir combined with ritonavir have been defined. This study evaluated the pharmacokinetics of 400 mg of indinavir/m2 combined with 125 mg of ritonavir/m2 every 12 h (q12h) in 14 human immunodeficiency virus type 1-infected children. The area under the concentration-time curve from 0 to 24 h and the minimum concentration of drug in serum for indinavir were similar to those for 800 mg of indinavir-100 mg of ritonavir q12h in adults, while the maximum concentration of drug in serum was slightly decreased, with geometric mean ratios (90% confidence intervals in parentheses) of 1.1 (0.87 to 1.3), 0.96 (0.60 to 1.5), and 0.80 (0.68 to 0.94), respectively.

* Corresponding author. Mailing address: Department of Clinical Pharmacy, University Medical Center, P.O. Box 9101, 533 KF, 6500 HB Nijmegen, The Netherlands. Phone: 31.24.3616405. Fax: 31.24.3540331. E-mail: d.burger{at}akf.umcn.nl.

Antimicrobial Agents and Chemotherapy, May 2004, p. 1904-1907, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1904-1907.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Puthanakit, T., van der Lugt, J., Bunupuradah, T., Ananworanich, J., Gorowara, M., Phasomsap, C., Jupimai, T., Boonrak, P., Pancharoen, C., Burger, D., Ruxrungtham, K. (2009). Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. J Antimicrob Chemother 64: 1080-1086 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»